Literature DB >> 2143418

Lipoprotein(a) binding to other apolipoprotein B containing lipoproteins.

V N Trieu1, W J McConathy.   

Abstract

A method combining ligand dot blotting and digital imaging was used to determine the apparent dissociation constant (KD) for the binding of lipoprotein(a) to low-density lipoproteins (Lp(a)-LDL2). By use of this approach, the KD for the Lp(a)-LDL2 complex was shown to be in the nanomolar range [(1.05 +/- 0.21) x 10(-8) M, n = 4]. The Lp(a)-LDL2 interaction was both hydrophobic and ionic; however, hydrophobic forces predominated because the interaction was demonstrable at high salt concentration (greater than 2 M NaCl), while no complex was detectable at low salt concentration (less than 0.08 M NaCl). Consistent with the hydrophobic nature of this interaction, the Lp(a)-LDL2 complex was stable over a wide pH range (4-10). Plasminogen did not compete with Lp(a) binding to LDL2 even at a 2.2 X 10(3) molar excess of plasminogen over the LDL2 concentration. The only component identified in plasma and serum that inhibited the binding of LDL2 to Lp(a) was apolipoprotein B containing lipoproteins (apoB-Lp). These studies indicate that the Lp(a)-LDL2 complex could exist in plasma. In fact, up to 72% of purified Lp(a) added to an Lp(a)-negative hypertriglyceridemic plasma floated with apoB-Lp (d less than 1.063 g/mL) following ultracentrifugation, whereas only 9% of the purified Lp(a) added to the apoB-Lp-free 1.12 g/mL infranate floated at d less than 1.063 g/mL. The formation of a complex of Lp(a) with apoB-Lp could increase the amount of cholesterol ester bound per cellular receptor, e.g., LDL receptor, and thus potentially accelerate cholesterol removal from the vascular compartment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143418     DOI: 10.1021/bi00477a006

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a).

Authors:  C Sandholzer; G Feussner; J Brunzell; G Utermann
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Fluorescence labeling and interaction of atherogenic lipoproteins with cultured cells.

Authors:  G Hofer; R Gorges; G M Kostner; F Paltauf; A Hermetter
Journal:  J Fluoresc       Date:  1994-12       Impact factor: 2.217

3.  10th International Conference on Methods in Protein Structure Analysis. September 8-13, 1994, Snowbird, Utah. Short communications and abstracts.

Authors: 
Journal:  J Protein Chem       Date:  1994-07

4.  Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia.

Authors:  D A Hardman; C R Pullinger; R L Hamilton; J P Kane; M J Malloy
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

5.  The apolipoprotein B3304-3317 peptide as an inhibitor of the lipoprotein (a):apolipoprotein B-containing lipoprotein interaction.

Authors:  V N Trieu; U Olsson; W J McConathy
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

6.  Proposed mechanisms for binding of apo[a] kringle type 9 to apo B-100 in human lipoprotein[a].

Authors:  J Guevara; J Spurlino; A Y Jan; C Y Yang; A Tulinsky; B V Prasad; J W Gaubatz; J D Morrisett
Journal:  Biophys J       Date:  1993-03       Impact factor: 4.033

Review 7.  Lipoprotein(a): new insights into an atherogenic lipoprotein.

Authors:  W Bartens; C Wanner
Journal:  Clin Investig       Date:  1994-08

8.  The binding of animal low-density lipoproteins to human apolipoprotein(a).

Authors:  V N Trieu; W J McConathy
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

9.  Human apoB contributes to increased serum total apo(a) level in LPA transgenic mice.

Authors:  Päivi A Teivainen; Knut A Eliassen; Edward M Rubin; Srdjan Djurovic; Kåre Berg
Journal:  Lipids Health Dis       Date:  2004-05-11       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.